Диссертация (1174208), страница 47
Текст из файла (страница 47)
M. Massaro, U. Hoffmann,R. T. Chung // J. Hepatol. – 2017. – V. 66. – P. 390–397.201. Machado, M. V.PathogenesisofNonalcoholicSteatohepatitis/M. V. Machado, A. M. Diehl // Gastroenterology. – 2016. – V. 150. – P. 17691777.202. Machado, M. V.Gut microbiota and nonalcoholic fatty liver disease /M. V.
Machado, H. Cortez-Pinto // Ann. Hepatol. – 2012. – V. 11. – P. 440-449.203. Mantovani, A. Nonalcoholic fatty liver disease is associated with ventriculararrhythmias in patients with type 2 diabetes referred for clinically indicated 24-302hour Holter monitoring / A. Mantovani, A. Rigamonti, S. Bonapace // DiabetesCare. – 2016. – V. 39.
– P. 1416–23.204.Marzuillo P., Miraglia del Giudice E., Santoro N. Pediatric fatty liverdisease: Role of ethnicity and genetics / P. Marzuillo, E. Miraglia del Giudice,N. Santoro // World J. Gastroenterol. – 2014/ – V. 20. – P. 7347–7355.205. Mc Cullough, A. J. The epidemiology and risk factors of NASH / A.
J. McCullough // Hepatology. – 2013. – V. 58, № 5. – P. 1644–1654.206. Michelotti, G.A. NAFID, NASH and liver cancer / G. A. Michelotti,M. V. Machado // Nat. Rev. Gastroenterol. Hepatol. – 2013. – №10. – P. 656–660.207. Micolasevic, I.Transientelastography(FibroScan)withcontrolledattenuation parameter in the assessment of liver steatosis and fibrosis in patientswith nonalcoholic fatty liver disease – Were dо we stand? / I.
Micolasevic,L. Orlic, N. Franjic, G. Hauser, D. Stimac, S. Milic // World J. Gastroenterol. –2016. – V. 22 (32). – P. 7236–7251.208. Motamed, N. Fatty liver index vs waist circumference for predicting nonalcoholicfattyliverdisease/N. Motamed,M. Sohrabi,H. Ajdarkosh,G. Hemmasi, M. Maadi, F. Sima // World J Gastroenterol. – 2016. – 22(10). – P.3023–3030.209.
Nasr, P. Natural history of nonalcoholic fatty liver disease: A prospectivefollow-up study with serial biopsies / P. Nasr, S. Ignatova, S. Kechagias,M. Ekstedt // Hepatol. Commun. – 2018. – V. 2. – P.199–210.210. Nonalcoholic fatty liver disease: a systematic review / M. E. Rinella //JAMA. – 2015. – V. 313. – P. 2263–2273.211. Oh, H. Non-alcoholic fatty liver diseases: update on the challenge ofdiagnosis and treatment / H. Oh, D.
W. Jun, W. K. Saeed, M. H. Nguyen // Clin.Mol. Hepatol. – 2016. – V. 22 (3). – P. 327–335.212. Oni, E. T. A systematic review: burden and severity of subclinicalcardiovascular disease among those with nonalcoholic fatty liver; should we care? /E. T. Oni, A. S. Agatston, M. J. Blaha, J. Fialkow, R. Cury, A. Sposito, R. Erbel,303R. Blankstein, T.
Feldman, M. H. Al-Mallah // Atherosclerosis. – 2013. – V. 230(2). – P. 258–67.213. Pacana, T. The cardiovascular link to nonalcoholic disease / T. Pacana //Clin. Liver Dis. – 2012. – №16. – Р. 599–613.214. Pallayova, M. Non-alcoholic fatty liver disease in obese adults: clinicalaspects and current management strategies / M. Pallayova, S. Taheri // Clin. Obes.– 2014. – V. 4 (5). – P. 243–53.215.
Pappachan, J. M.Non-alcoholic fatty liver disease: a diabetologist'sperspective / J. M. Pappachan, F. A. Antonio, M. Edavalath, A. Mukherjee //Endocrine. – 2014. – V. 45 (3). – P. 344–53.216. Pavlov, C. S. Systematic reviewwith meta-analysis: Diagnostic accuracy oftransient elastography for staging of fibrosisin people with alcoholic liver disease /C. S.
Pavlov, G. Casazza, D. Nikolova, E. Tsochatzis, C. Gluud // AlimentaryPharmacology & Therapeutics. – 2016. – V. 43, №. 5. – P. 575–585.217. Perseghin, G. Hypertension and hepatic triglycerides content: a two (multi)faceted clinical challenge? / G. Perseghin, G. Manzoni, G. Grassi // Journal ofHypertension. – 2017. – V. 35 (4). – P. 715–717.218.Perseghin, G. Abnormal left ventricular energy metabolism in obese menwith preserved systolic and diastolic functions is associated with insulin resistance/ G.
Perseghin, G. Ntali, F. De Cobelli, G. Lattuada, А. Esposito, Е. Belloni// Diabetes Care, – 2007. – V. 30 (6). – Р.1520–1526.219. Perumpail, B. J. Clinical epidemiology and disease burden of nonalcoholicfatty liver disease. / B. J. Perumpail, M. A. Khan, E. R. Yoo, G. Cholankeril,D. Kim, A. Ahmed // World J. Gastroenterol. – 2017. – V. 23 (47).
– P. 8263–8276.220. Petrović, G. Obesity and metabolic syndrome as risk factors for thedevelopment of non-alcoholic fatty liver disease as diagnosed by ultrasound. /G. Petrović,G. Bjelaković,D. Benedeto-Stojanov,A. Nagorni,V. Brzački,B. Marković-Živković // Vojnosanit Pregl. – 2016. – V. 73 (10). – P. 910–20.304221. Petta, S. Visceral инетреfibrosity index is associated with significantfibrosis in patients with non-alcoholic fatty liver disease / S. Petta, M.C. Amato, V.Di Marco et al.
// Aliment Pharmacol Ther. – 2012. – №35. – Р. 238–247.222. Petta, S. Special Interest Group on Personalised Hepatology of the ItalianAssociation for the Study of the Liver (AISF) Special Interest Group onPersonalised Hepatology of Italian Association for Study of Liver AISF A«systems medicine» approach to the study of non-alcoholic fatty liver disease /S.
Petta, L. Valenti, E. Bugianesi, G. Targher, S. Bellentani, F. Bonino // Dig.Liver Dis. – 2016. –V. 48. – P. 333–342.223. Pastori, D. The efficacy and safety of statins for the treatment of nonalcoholic fatty liver diseas / D. Pastori // Dig. and Liv. Dis. – 2015. – Vol. 47, № 1.– P. 4–11.224. Povero, D. Feldstein AE.
Novel Molecular Mechanisms in the Developmentof Non-Alcoholic Steatohepatitis / D. Povero, A. E. Feldstein // Diabetes Metab. J.– 2016. – V. 40. – P. 1–11.225. Praveenraj, Р. Prevalence and Predictors of Non-Alcoholic Fatty LiverDisease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery /P. Praveenraj,R. M. Gomes,S. Kumar,P. Karthikeyan,A. Shankar,R. Parthasarathi, P. Senthilnathan, S. Rajapandian, C. Palanivelu // Obes.
Surg. –2015. – V. 25 (11). – P. 2078–87.226. Rasool, А. Nonalcoholic fatty liver disease as an independent risk factor forcarotid atherosclerosis / A. Rasool, W. Dar, M. Latief, I. Dar, N. Sofi, M. A. Khan// Brain Circ. – 2017. – V. 3 (1). – P. 35–40.227. Rath, M. M. Histological Evaluation of Non-alcoholic Fatty Liver Diseaseand Its Correlation with Different Noninvasive Scoring Systems with SpecialReference to Fibrosis: A Single Center Experience / M.M. Rath, M. K. Panigrahi,K. Pattnaik, P. Bhuyan, S.
K. Kar, B. Misra, D. Misra, C. Meher, O. Agrawal,J. Rath // J. Clin. Exp. Hepatol. – 2016. – V. 6 (4). – P. 291–296.228. Ratziu, V. Current efforts and trends in the treatment of NASH / V. Ratziu,Z. Goodman, A. Sanyal // J. Hepatol. – 2015. – V. 62. – P. 65–75.305229. Salvi, P. Increased arterial stiffness in nonalcoholic fatty liver disease: theCardio-GOOSE study / P. Salvi, R. Ruffini, D. Agnoletti // J. Hypertens. – 2010. –V. 28 (8). – P. 1699–1707.230. Sayiner, M.
Epidemiology of Nonalcoholic Fatty Liver Disease andNonalcoholic Steatohepatitis in the United States and the Rest of the World /M. Sayiner, A. Koenig, L. Henry, Z. M. Younossi // Clin, Liver Dis. – 2016. –V. 20 (2). – P. 205–14.231. Sanyal, A.J. Putting non-alcoholic fatty liver disease on the radar for primarycare physicians: how well are we doing? / A. J.
Sanyal // BMC Medicine. – 2018. –V. 16 (1). – P. 148–158.232. Serra-Planas, E. Low prevalence of non-alcoholic fatty liver disease inpatients with type 1 diabetes is associated with decreased subclinicalcardiovascular disease / E. Serra-Planas, E. Aguilera, L. Castro, R. Rodríguez,I. Salinas, A.
Lucas, C. Joaquín, R. Puig, D. Mauricio, M. J. Puig-Domingo //Diabetes. – 2017. – V. 9 (12). – P. 1065–1072.233. Sears, D. D. Fatty liver: Medscape reference (updated Dec 14, 2014) /D. D. Sears,B. S. Anand.–Режимдоступа:http://emedicine.medscape.com/article/175472-overview.234.
Shashaj, B. Reference ranges of HOMA-IR in normal-weight and obeseyoungCaucasians/B. Shashaj,R. Luciano,B. Contoli,G. S. Morino,M. R. Spreghini, C. Rustico, R. W. Sforza, B. Dallapiccola, M. Manco // ActaDiabetol. – 2016. – V. 53 (2). – P. 251–260.235. Shen, F. Controlled attenuation parameter for non-invasive assessment ofhepatic steatosis in Chinese patients / F. Shen, R. D. Zheng, Y. Q. Mi, X. Y. Wang,Q.
Pan, G. Y. Chen // World Journal of Gastroenterology. – 2014. – V. 20 (16). –P. 4702–4711.236. Shulman, G. I. Ectopic fat in insulin resistance, dyslipidemia, andcardiometabolic disease / G. I. Shulman // N. Engl. J. Med. – 2014. – V. 371. –P. 1131–1141.306237. Singh, S. Fibrosis Progression in Nonalcoholic Fatty Liver vs NonalcoholicSteatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies/ S. Singh, A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad, R. Loomba //Clinical Gastroenterology and Hepatology. – 2015. – V. 13 (4). – P. 643–654.238.
Smolka, V. Relation of risk factors between metabolic syndrome andnonalcoholic fatty liver disease in children and adolescents / V. Smolka,J. Jr. Ehrmann, O. Tkachyk, M. Zápalka // Cas. Lek. Cesk. – 2014. – V. 153 (2). –P. 91–7.239. Soderberg, C. Decreased survival of subjects with elevated liver functiontests during a 28-year follow-up / C.
Soderberg, P. Stal, J. Askling // Hepatology. –2010. – V. 51. – P. 595–602.240. Sookoian, S. Systematic review with meta-analysis: risk factors for nonalcoholic fatty liver disease suggest a shared altered metabolic and cardiovascularprofile between lean and obese patients / S.
Sookoian, C. Pirola // AlimentPharmacol Ther. – 2017. – V. 46 (2). – P. 85–95.241. Sumida, Y. Limitations of liver biopsy and non-invasive diagnostic tests forthe diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis / Y.Simida // World J. Gastroenterol. – 2014. – V. 20 (2). – P. 475–485.242. Sung, K. C. Interrelationship between fatty liver and insulin resistance in thedevelopment of type 2 diabetes. / K. C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
